Clinical Topics

Metformin Promising for Improving Prostate Cancer Survival

by U.S. Medicine

September 9, 2018

MADISON, WI—Metformin, a commonly used drug for patients with Type 2 diabetes mellitus (DM), has shown promise in helping to treat prostate cancer (PCa), according to a new study.

The report in the Journal of Urology posited that metformin plus androgen deprivation therapy (ADT) might be beneficial in combination. To do that, a research team from the William S. Middleton Memorial Veterans Hospital and the University of Wisconsin-Madison performed a retrospective cohort of patients with advanced PCa.1

The investigators used the national VA database to identify all men diagnosed with PCa between 2000-2008 who were treated with ADT with follow-up through May of 2016. Excluded from the study were patients who had received ADT for six months or less or who had undergone the therapy concurrent with localized radiation.

In the cohort after exclusions were 87,344 patients divided into three cohorts: 61% were no DM, 22% were DM no metformin, and 17% were DM on metformin. Hazard ratios were calculated for overall survival (OS), skeletal-related events (SRE) and cancer-specific survival (CSS).

Results indicated that OS showed improved survival in DM on metformin (HR 0.82, 95% CI 0.78-0.86) vs. DM no metformin (HR 1.03, 95% CI 0.99-1.08) with no DM as referent group.

In addition, the study team noted, research revealed HR 0.82 (95% CI 0.72-0.93) for DM on metformin, while Cox proportional hazards analysis for CSS showed improved survival in DM on metformin (HR 0.70, 95% CI 0.64-0.77) vs. DM with no metformin (HR 0.93, 95% CI 0.85- 1.00), using no DM as a referent group.

“Metformin use in veterans with PCa receiving ADT is associated with improved oncologic outcomes,” study authors concluded. “This association should be evaluated in a prospective clinical trial.”

1. Richards KA, Liou JI, Cryns VL, Downs TM, Abel EJ, Jarrard DF. Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol. 2018 Jun 22. pii: S0022-5347(18)43412-X. doi: 10.1016/j.juro.2018.06.031. [Epub ahead of print] PubMed PMID: 29940252.

Related Articles

“Coming together is a beginning. Keeping together is progress. Working together is success.” — Henry Ford (1863-1947)

October is Operation Bushmaster season for Uniformed Services University (USU) medical and nursing students.

NASA Partners with Academia for CVD Prediction Tool in Younger Adults

Federal medicine played a crucial role in the development of a new online tool to better predict which middle-aged adults are at the greatest risk of having acute myocardial infarction or stroke over the next decade.

U.S. Medicine Recommends

More From oncology


VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.


VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.


Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.


Side-effects Differ Between Radiation Therapies for Prostate Cancer

A recent study compared patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.


Parkinson's Drug Not Associated With Higher Prostate Cancer Risk

An increased incidence of prostate cancer was observed in Parkinson's disease (PD) patients treated with entacapone during a pre-approval randomized clinical trial, according to a new study which noted that the relationship had not yet been intensely investigated.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up